In MUM, the main challenge is finding truly tumor-restricted surface targets—because melanocytic differentiation antigens (e.g., TYRP1, GD2, B7-H3, HER2) are variably expressed on normal eye and skin tissue—yet several pre-clinical programs are beginning to address this gap. This evidence concerns the gene ERBB2 and neoplasm.